Novocure Launches Clinical Trial Website at www.novocuretrials.com

New website provides patients and their families with educational information regarding ongoing clinical trials testing Tumor Treating Fields in a variety of solid tumor cancers

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today the launch of its new clinical trial website at www.novocuretrials.com. The website is intended to serve as a resource for patients suffering from solid tumor cancers and their families who seek information regarding clinical trials testing Tumor Treating Fields (TTFields). The website provides basic information about TTFields, the design of ongoing and planned company-sponsored trials, the target population for each trial, and trial locations. The website is available in nine languages.

“Many cancer patients do not seek out clinical trials and remain unaware of experimental treatment options,” said Uri Weinberg, MD, PhD, Novocure’s Vice President for Research and Development. “We believe that this new website will be an important tool for patients and their families by allowing them access to information about our growing clinical trial pipeline and information on how they can contact study centers to seek participation in these innovative studies.”

The website, located at www.novocuretrials.com, currently provides information on the following four ongoing trials.

  • PANOVA: A Phase 2 study of TTFields combined with chemotherapy for newly-diagnosed pancreatic cancer
  • INNOVATE: A Phase 2 study of TTFields combined with chemotherapy for recurrent ovarian cancer
  • STELLAR: A Phase 2 study of TTFields combined with chemotherapy for mesothelioma
  • COMET: A Phase 2 study of TTFields following local therapy for 1-5 brain metastasis from non-small-cell-lung cancer

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. TTFields therapy is not approved for the treatment of pancreatic cancer, ovarian cancer, mesothelioma or brain metastasis from non-small-cell-lung cancer. The safety and effectiveness of TTFields therapy in these indications has not been established.

Approved Indication

The US FDA has approved the TTFields therapy delivery system, Optune (previously known as the NovoTTF-100A System), for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301.

About Novocure

Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Contacts

Media and Investors:
Novocure
Ashley Cordova, 212-767-7558
acordova@novocure.com